Cellectis S.A.

NASDAQ:CLLS

Biotechnology

Healthcare
$1.03 -0.65%

-$0.02 today

Market cap
$103.75M
Beta
2.75
P/E (TTM)
-4.6
EPS (TTM)
-$0.67
52W Low $1.35High $5.48

Volume 0.01M

Average 0.04M

CLLS Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Cellectis S.A.NASDAQ: CLLS

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 100.53M shares rose 0.4% year over year, behind the +2.9% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.2% from the prior quarter. Over 3 fiscal years it compounded at +30.1% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +0.4% toward the trailing-twelve-month pace of +2.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
100.53M+0.2% QoQ
Last fiscal yearDec 2025
100.28M+10.7% YoY
LTMMar 2026
100.38M+2.9% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.4%——
1 year+10.7%——
3-year CAGR+30.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
100.28M USD
Year-over-year change
+10.7%
4-year CAGR
+22.3%

Weighted Avg Shares vs competitors

How CLLS compares with its peers on the latest reported figures

  • CLLS's LTM Mar 2026 weighted avg shares of 100.38M shares is the 2nd highest of the 11 companies compared; the peer median is 69.17M shares.
  • Its year-over-year change of +2.9% is the 6th highest of 10, against a peer median of +5.1%.
  • Over three fiscal years its annual growth of +30.1% compares with a peer median of +7.3%.
CLLS Competitors Peer median
Weighted Avg Shares for CLLS and competitors
Company Period LTM YoY 3-year CAGR
MREOMereo BioPharma Group plcLTM Mar 2026159.92M +5.1%+9.7%
CLLSCellectis S.A.LTM Mar 2026100.38M +2.9%+30.1%
ACIUAC Immune S.A.LTM Mar 202699.9M -2.5%+6.4%
DBVTDBV Technologies S.A.LTM Mar 202688.66M -7.8%+3.7%
DRTSAlpha Tau Medical Ltd.LTM Mar 202684.87M +21.1%+8.2%
LRMRLarimar Therapeutics, Inc.LTM Mar 202678.18M +22.5%+41.5%
ALDXAldeyra Therapeutics, Inc.LTM Mar 202660.16M +1.0%+0.9%
SLNSilence Therapeutics plcLTM Mar 202631.49M —+63.9%
ANROAlto Neuroscience, Inc.LTM Mar 202629.75M +10.2%+4.1%
AMRNAmarin Corporation plcLTM Mar 202620.78M +1.0%+1.1%
KRROKorro Bio, Inc.LTM Mar 20269.94M +8.7%+232.8%
Peer median (excluding CLLS) 69.17M+5.1%+7.3%

Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.35M19.17M755K41.51M72.95M
Cost of Revenue1.84M8.48M7.42M9.18M9.8M
Gross Profit28.5M10.69M(6.66M)32.32M63.15M
Gross Margin93.9%55.7%-882.6%77.9%86.6%
Research & Development117.84M97.5M87.65M90.54M93.52M
Selling, General & Admin22.88M8.9M8.12M8.42M8.6M
Operating Expenses131.98M100.35M90.64M91.88M96.23M
Depreciation & Amortization14.16M18.44M18.52M19.85M20.06M
EBITDA(78.43M)(76.38M)(92.64M)(9.46M)(39.85M)
EBITDA Margin-258.4%-398.4%-12269.8%-22.8%-54.6%
Operating Income(103.48M)(89.67M)(97.3M)(59.55M)(33.08M)
Operating Margin-341.0%-467.7%-12887.7%-143.5%-45.3%
Interest Income719K1.12M3.61M11.28M9.5M
Interest Expense4.37M3.79M5.31M7.45M8.11M
Other Income / Expenses6.73M(8.94M)(19.16M)22.79M(34.94M)
Income Before Tax(96.75M)(98.6M)(116.46M)(36.76M)(68.02M)
Pre-Tax Margin-318.8%-514.3%-15425.7%-88.6%-93.2%
Income Tax Expense(3K)87K371K0(423K)
Net Income(114.2M)(106.14M)(101.06M)(36.76M)(67.59M)
Net Margin-376.3%-553.6%-13385.3%-88.6%-92.7%
EPS (Basic)(1.93)(2.33)(1.77)(0.41)(0.68)
EPS (Diluted)(1.93)(2.33)(1.77)(0.41)(0.68)
Weighted Avg Shares44.82M45.55M57.01M90.57M100.28M
Weighted Avg Shares (Diluted)44.82M45.55M57.01M90.57M100.28M

Cellectis S.A.

NASDAQ:CLLS

Intrinsic Alpha fair value

Locked

Current Price

$1.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.